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The MauiDerm annual educational meeting, sponsored by Advances in Cosmetic and Medical Dermatology, aims to increase
physician knowledge in the areas of both medical and cosmetic dermatology. MauiDerm’s world-renowned experts have
discussed significant advances in the diagnosis, management, and treatment of both medical and cosmetic dermatologic
conditions at a very high scientific level. This supplement to The Journal of Clinical and Aesthetic Dermatology is based upon
the proceedings from the cutaneous oncology, psoriasis, and psoriatic arthritis sessions that took place at the 2015 MauiDerm
Meeting.
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Psoriasis Update
Psoriasis is an immunologically mediated systemic
disease involving both the skin and joints. A growing
understanding of immunologic pathways has created
interest in treating psoriasis with targeted biologics, such
as the well-known tumor necrosis factor alpha (TNF-α)
inhibitors etanercept, infliximab, and adalimumab. Two
other TNF inhibitors, golimumab and certolizumab
pegol, have been shown effective against plaque psoriasis
in clinical studies of psoriatic arthritis.1 An important
new small molecule for treating both psoriasis and
psoriatic arthritis is apremilast, approved for commercial
release by the United States Food and Drug
Administration (FDA) in September 2014.
Apremilast is a phosphodiesterase-4 (PDE4) enzyme
inhibitor that blocks leukocyte production of interleukin
(IL)-12, IL-23, TNF-α, and interferon (INF)-γ and
suppresses the immune responses mediated by Th1 and
Th17.2 Apremilast was approved for both psoriatic
arthritis and psoriasis. 
In a phase 3, multicenter, double-blind, placebo-
controlled study, 844 patients were randomized in a 2:1
ratio to receive apremilast or placebo for the treatment
of moderate-to-severe plaque psoriasis.3 Patients were
treated with apremilast 30mg twice a day with or without
topicals and ultraviolet-B phototherapy. Doses of
apremilast were titrated during the first week of
administration and again at Week 16 when placebo
patients were switched to apremilast. At 16 weeks, more
patients in the apremilast group achieved PASI-75 than
placebo (33.1 vs. 5.3%, p<0.001). 
A second phase 3 clinical study, ESTEEM 2, has not
yet been published, but examines the use of apremilast
in nail, scalp, and palmoplantar psoriasis.4 Adverse
events in ESTEEM 1 were mild to moderate. In the
placebo-controlled portion of the study, 55.7 versus 69.3
percent of placebo versus apremilast patients,
respectively, reported at least one adverse event.3 It
should be noted that no new adverse events were
reported after Week 16, and the incidence of serious
adverse events was 2.8 percent for apremilast versus 2.1
percent for placebo. The most frequently reported
adverse events based on pooled data from ESTEEM 1
during the first 16 weeks were diarrhea (18.8 vs. 7.1% for
apremilast vs. placebo patients, respectively) and nausea
(15.7 vs. 6.7%, respectively). Other adverse events
reported in ESTEEM 1 include upper respiratory tract
infection, nasopharyngitis, and headache. The
discontinuation rates owing to adverse events were low
(1.8% in apremilast group and 0.4% in placebo group).
Apremilast was shown in another study to produce a
slightly higher response rate in patients who had
received no prior systemic or biologic therapy.5
Apremilast was associated with transient abnormal
laboratory parameters, which investigators deemed as
not clinically significant. Further studies will examine the
effect of apremilast versus placebo on pruritus, weight
loss, and psychiatric disorders. According to product
labeling, in the 0- to 16-week placebo-controlled period
of three controlled clinical studies, 1.3 percent of
apremilast patients versus 0.4 percent of placebo
patients reported depression.6 Product labeling also
warns about weight decrease,6 the mechanism of action
for which remains unknown. Patients with both high and
low body mass index (BMI) may lose as much as five
percent of total body weight.
With psoriasis, durable results remain a clinical
challenge. Data extracted from a prospective registry in
the Netherlands were analyzed for one-year survival with
adalimumab, etanercept, and ustekinumab for so-called
“happy drug survival,” defined as a score on the
Dermatology Life Quality Index (DLQI) ≥5 at 3, 6, 9, and
12 months.7 At baseline, 73 percent of patients could be
considered “unhappy.” The percentage of treatment
episodes with “happy” patients taking drugs increased to
79 percent after one year. Ustekinumab showed better
overall drug survival than etanercept and a trend toward
better overall survival than adalimumab.7
PSOLAR is a large, ongoing, international,
observational registry of more than 12,000 psoriasis
patients treated with biologics (infliximab, ustekinumab,
adalimumab, and etanercept) and other agents.
Cumulative rates are 0.46 per 100 patient years for
death, 0.26 per 100 patient years for a major adverse
cardiovascular event (MACE), 0.68 per 100 patient years
for malignancy, and 1.50 per 100 patient years for a
serious infection.8 Notable in these findings is that age
was a significant predictor for all adverse events of
interest. Compared to nonbiologic treatments for
psoriasis, the use of biologics is not a significant
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predictor of death, MACE, or malignancy and the
PSOLAR data through 2013 revealed no new safety
concerns.8 A more recent analysis of PSOLAR data found
a higher risk for serious infections with adalimumab and
infliximab (but not ustekinumab or etanercept) versus
nonbiologic and non-methotrexate therapies.9
Interpatient pharmacokinetic variability, differences
in therapeutic response, drug immunogenicity, and the
natural fluctuations in the course of a chronic condition,
such as psoriasis, may lead to off-label dosing (both dose
escalation and reduction). Using the Spanish Registry for
Systemic Treatments in Psoriasis (BIOBADERM), which
includes data from approximately 2,000 moderate-to-
severe psoriasis patients translating to 5,383 person-
years, dose reduction, usually achieved by extending the
dosing interval, occurred mainly in patients treated with
adalimumab (41.3%), infliximab (33.3%), ustekinumab
(30.9%) and infliximab (29.4%).10
Using statistical regression, the risk of dose reduction
increased by eight percent for every five percent
improvement in Psoriasis Area and Severity Index
(PASI) at the cutoff date. On the other hand, dose
escalation occurred with infliximab (13.7%),
ustekinumab (10.4%), etanercept (7.9%), and
adalimumab (2.2%), accomplished primarily by
truncating the dosing interval. There were 2,209
discontinuations over the course of the study, the main
reasons for which were lack of efficacy (36.4%) and
disease remission (27.2%). Further, for each additional
biologic agent, the odds increased 85 percent for dose
escalation. The BIOBADERM analysis found that about
40 percent of moderate-to-severe psoriasis patients on
biologic therapy were receiving an off-label dose; dose
escalation was more frequent for ustekinumab and
infliximab.10
Principles of Topical Therapy: Maintenance
Strategies and Future Directions
Despite the growing academic interest in biologics,
most psoriasis patients today are treated topically, and
emerging topical therapies may offer important
advantages in psoriasis treatment.11 Some of these new
molecules and new formulations are discussed below,
along with strategies to maintain remission in topical
treatment of psoriasis. 
When a patient is cleared with topical therapy, the
prescriber must arrive at a strategy for long-term
maintenance, such as a “drug holiday.” In a placebo-
controlled study of psoriasis patients treated with
betamethasone dipropionate in an optimized vehicle
twice daily, 38/59 patients had 85-percent improvement
or greater versus baseline.12 Of these patients, 74 percent
could maintain remission with treatment on weekends
only, compared to 21 percent who maintained remission
with vehicle only. In an open-label, multicenter study of
316 psoriasis patients treated with clobetasol propionate
intermittently over 14 days, 62 percent achieved
clearance.13 When 132 of the cleared patients were put
on a twice-weekly maintenance schedule, 75 percent of
patients remained clear.
Patient compliance is crucial to good results with
topical therapy. In a randomized trial of 885 scalp
psoriasis patients, patients were maintained on a
formulation of calcipotriol (50µg.g) and betamethasone
dipropionate (0.5mg/kg) either by using it twice weekly
(Group A) or by using it on demand (Group B).14 After
two weeks and at evaluations on 4, 8, and 12 weeks, both
groups showed significant improvement over baseline,
but at 8 and 12 weeks, Group A had a significantly
improved clinical response compared to Group B
(p<0.05). Group A patients had a significantly lower
relapse rate compared to Group B (19.5 vs. 41.7%,
p<0.001).14 Thus, even well-maintained patients may
benefit from fixed scheduling.
The vehicle can have a substantial impact on how well
and deeply the topical agent penetrates the skin. In fact,
changing the vehicle may change the product’s potency,
as is the case with mometasone furoate, a high-potency
Class II topical when prepared in a 0.1% ointment, but is
a mid-potency Class IV in a 0.1% cream product.
Desoximetasone is another example, which is more
potent as a new spray product (Class I) than previous
formulations.15
A number of new molecules for topical therapy are on
the horizon; in some cases these “new” molecules are
established drugs being reformulated for potential
topical treatments. Data are not yet available for a new
fixed combination of tazarotene and halobetasol for
psoriasis. Topical halobetasol propionate 0.5% ointment
is a Class I corticosteroid with demonstrated efficacy as
monotherapy against plaque psoriasis.16 It may be
combined with tazarotene without affecting the stability
of halobetasol and may offer synergistic efficacy.16,17
Calcipotriene combined with betamethasone
dipropionate for pediatric scalp psoriasis was shown
effective in a prospective observational study, including
84 treatment episodes.18 At 12 weeks, the Psoriasis Scalp
Severity Index (PSSI) showed significant improvement
with treatment (18.7%±11.8 to 12.7±9.4) and this result
could be maintained over 48 weeks of follow-up. This
combination of calcipotriene and betamethasone
dipropionate had previously been shown to be more
effective in the treatment of adult scalp psoriasis than
either agent in monotherapy.19,20 In an older multicenter
study, combination therapy of halobetasol plus
calcipotriene was tested against these two agents as
monotherapies for treating psoriasis in adults.21 Patients
used calcipotriene ointment 0.005% mornings and
halobetasol propionate ointment 0.05% in the evening
versus either calcipotriene or halobetasol ointment (as
monotherapy) applied twice daily in a study of 127
patients with moderate plaque psoriasis. Efficacy was
better for combination treatment (71% for combination
vs. 57% for halobetasol alone and 30% for calipotriene
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alone), and combination therapy resulted in fewer
cutaneous side effects compared to calcipotriene alone.21
In a study of 86 plaque psoriasis patients treated with
twice-daily clobetasol foam plus calcipotriene ointment
versus these agents in monotherapy, combination
patients achieved significantly lower psoriasis scores
(p<0.001) at two weeks compared to monotherapy
patients.22 Adjusted trunk lesion scores were 0.67 for
combination therapy, 1.40 for calcipotriene alone, and
1.13 for clobetasol foam alone. Combination therapy
patients who remitted received weekday calcipotriene
therapy and on weekends used clobetasol foam or
vehicle for six months; during this phase, clobetasol foam
trended toward greater maintenance of remission versus
vehicle (92% improvement of trunk lesions vs. 62%,
respectively).22
Calcipotriene is available commercially as an
ointment, a solution, a cream, a fixed-dose combination
ointment product with betamethasone dipropionate, and
most recently as an aqueous-based foam. In two
identical, randomized, double-blind, vehicle-controlled,
eight-week studies, 659 plaque psoriasis patients were
randomized to receive calcipotriene 0.005% foam or
vehicle, twice daily.23 Based on intention-to-treat
analysis, treatment success in the first of the two studies
occurred in 14 percent of calcipotriene foam versus
seven percent of vehicle patients at eight weeks
(p=0.058). In the last-observation-carried-forward
(LOCF) analysis, calcipotriene foam was effective in 15
versus 7 percent of patients (p=0.034). In the second
study, calcipotriene foam patients had significantly
better results than vehicle foam patients (27 vs. 16%,
respectively, p=0.016); using LOCF analysis, results were
28 versus 16 percent, respectively, p=0.010). Adverse
events rates were similar between groups. Calcipotriene
foam 0.005% was also more effective than vehicle foam
on scalp psoriasis at eight weeks.24
Janus kinase (JAK) inhibitors are an important new
class of drugs with potential indications for psoriasis as
well as rheumatic disorders and several types of
cancer.25,26 The Janus family kinases include JAK1, JAK2,
JAK3, and TYK2, involved in cell growth, cell survival, as
well as cell development and differentiation.27 JAK
inhibitors block the barrage of cytokines bombarding a
given cell in an effort to have their unique signaling
cascade impact genetic transcription of that cell. These
bombarding cytokines include, but are not limited to,
TNF, immune complexes, and T-cell antigens.28 JAK
inhibitors block those bombarding cytokines; signal
transducer and activator transcription (STAT) signaling
pathways are activated by IL-2-produced cytokines,29 but
STAT transcription factors make less promising targets
for drug development as they lack enzymatic activity.30
Genetic mutations in the JAK-STAT pathway have been
implicated in many autoinhibitory dysfunctions,
including malignancies. Since psoriasis is associated with
a plethora of pro-inflammatory cytokines, JAK inhibitors
may offer promising new treatment options.31 For
example, tofacitinib is a new small molecule for
treatment of psoriasis and rheumatic disorders that
primarily inhibits JAK1/JAK3.29,32 Originally developed as
a selective JAK3 inhibitor for use in immunosuppression
secondary to transplantations, tofacitinib was found to
also inhibit JAK1 and was approved for treatment of
active rheumatoid arthritis in 2012.30 A selective JAK3
inhibitor is in development for psoriasis treatment.33
A novel JAK inhibitor (ASP015K, peficitinib)
demonstrated dose-dependent improvements in
moderate-to-severe psoriasis at six weeks with no
serious adverse events (n=124).34 Ruxolitinib, a selective
JAK1 and JAK2 inhibitor is in development and may be
useful in the treatment of psoriasis if formulated as a
topical product.35 A potential benefit of JAK inhibition is
that they can block signals from multiple (rather than
single) cytokines on a cellular level. 
Phosphodiesterase-4 (PDE4) inhibitors, such as
apremilast, are small molecules that may benefit patients
with psoriasis and psoriatic arthritis.36 A novel compound
(AN-2728) containing boron is currently being studied
for its use in a topical formulation in treating psoriasis
and atopic dermatitis.37 AN-2728 inhibits PDE4 activity,
and, in so doing, suppresses the release of TNF-α, IL-12,
and IL-23. Selective PDE4 inhibitors reduce
inflammation in almost all inflammatory cells and inhibit
TNF-α.
What’s New in Systemic Psoriasis Treatments?
Psoriasis is a T-cell-driven inflammatory cutaneous
disease,38,39 but there is differentiation between resident
T-cells and T-cells recruited from the circulation.40,41
Visually, nonlesional skin in the psoriasis patient may
appear devoid of inflammation, but often contains an
abnormally high number of resident T-cells in the dermis
and epidermis, and these resident T-cells may have a TH-
Figure 1. The cytokine and cytokine inhibitors relevant in chronic
inflammation associated with psoriasis
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1 cytokine secretion bias.40 Preclinical studies have
suggested the existence of an inflammatory axis in which
IL-17 and IL-23 play important roles. This notion is
supported by the observation that an agent targeting the
p40 antibody (shared by IL-12 and IL-23) improves
psoriatic lesions.42,43 A summary of the cytokine and
cytokine inhibitors associated with chronic inflammation
appears in Figure 1. Second-generation biologic agents,
such as adalimumab, etanercept, infliximab,and
certolizumab, for psoriasis treatment all target TNF-α.
Ustekinumab may be considered a third-generation
biologic; it antagonizes IL-12 and IL23 by way of its
unique p19 subunit, leading to downstream effects.
Secukinumab, an IL-17 antagonist, was shown effective
against psoriasis in two large randomized clinical trials.44
A summary of remarks on new drug development
appears in Table 1.
Secukinumab’s efficacy was related directly to its
serum concentration, an observation with particular
clinical relevance with regard to predicting therapeutic
response. Recommended doses are 150 and 300mg, but
the FDA recommended 450mg for higher-BMI patients,
even though the 450mg dose had not been tested.45
In a phase 2, double-blind, placebo-controlled study,
142 patients with moderate-to-severe plaque psoriasis
received subcutaneous ixekizumab (10, 25, 75, or
150mg) or placebo at 0, 2, 4, 8, 12, and 16 weeks.46 At 12
weeks, PASI scores of ≥75% were significantly greater for
ixekizumab patients at all but the 10mg dose: 82.1, 82.8,
76.7 percent for 150, 75, and 25mg, respectively, versus
7.7 percent placebo (p<0.001 for each). PASI 100% was
achieved by 39.3 and 37.9 percent of ixekizumab 150 and
75mg patients, respectively, versus 0 patients in the
placebo group (p<0.001 for both). Significant differences
emerged by the first week and were durable through
Week 20; adverse event rates were similar among all
groups, including placebo, and no serious adverse events
or MACE occurred. A subsequent analysis of study data
explored whether achieving a PASI-50 score was
predictive for achieving PASI-75 at 12 weeks and found a
PASI-50 had 90 percent specificity and 83 percent
sensitivity in this analysis.
In a 96-week, phase 2 study of brodalumab, 198
psoriasis patients were randomized to receive
brodalumab 70, 140, or 210mg at Day 1 and again on
Weeks 1, 2, 4, 6, 8, and 10 or 280 mg/month or placebo.47
The mean percentage improvements in PASI scores were
45.0 (70mg), 85.9 (140mg), 86.3 (210mg), and 76.0
percent (280mg/month) compared to 16.0 percent
placebo patients (p<0.001 for all versus placebo). By
Week 12, an improvement of at least 75 and 90 percent
occurred in 77 and 72 percent of all patients, respectively,
compared with 0 in the placebo group (p<0.001 for all).
Adverse events included nasopharyngitis (8%), upper
respiratory tract infection (8%), and injection-site
erhythema (6%).47 As these drugs are also still standard
drugs for the treatment of psoriatic arthritis, this finding
is particularly relevant as both conditions arise in about
one-third of those with plaque psoriasis.
The number-needed-to-treat (NNT) can be a valuable
real-world metric in appropriate prescribing, as it helps
convey effect size. NNT may be defined as the average
number of patients who need to be treated in order to
achieve one additional good outcome; as such, it is the
inverse of absolute risk reduction.48 Since many systemic
psoriasis treatments offer evident results in about four
weeks, there is little to no need for biomarkers to predict
response.
TABLE 1. A summary of new systemic drug therapies for psoriasis
DRUG CURRENT STATUS AND OBSERVATIONS COMMENTS
Certolizumab-Pegol Developed for treating Crohn’s disease
Ustekinumab Antagonizes IL-23 by targeting the p19 subunit(not shared)
Pure IL-23 antagonist; adverse events include
risk of serious infection
Guselkumab Phase 2 dose-ranging studies resulted in comparisons to adalimumab
Tidrakizumab
Phase 2 dose-ranging studied, good PASI-90
scores at 12 weeks. Antagonizes IL-23 by
targeting p19 subunit
Well-tolerated
Boehringer-Ingelheim 655066
Novel monoclonal antibody, phase 2 proof-of-
concept study with 58% achieving PASI-90 and
remaining clear at 66 weeks
Subcutaneous injection, may need dosing only
every four months
Secukinumab, ixekizumab, 
and brodalumab IL-17 antagonists
Secukinumab approved in U.S. for psoriasis in
May 2015
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The “stepwise approach” to psoriasis treatment was
replaced by individualized care. In the old model,
patients initiated psoriasis therapy with over-the-counter
(OTC) products and gradually progressed, step by step,
to prescription agents, phototherapy, and finally
systemic therapy. Each new step was only taken if the
patient failed the prior step. The emerging treatment
paradigm still recognizes two categories of psoriasis
patients (i.e., those who achieve good results with a
topical treatment versus those who clearly need more),
but rather than proceeding step-by-step through
increasingly more aggressive therapies, the choice of
therapy following topical treatment failure is based on
the patient’s individual characteristics. Thus, it may be
appropriate to move a particular patient from failed
topical therapy directly to a biologic with no intervening
steps (Figure 2). 
Despite novel therapies, even in the year 2000,
clearance was not considered a reasonable goal for
psoriasis treatment. Fortunately, the attainable and
reasonable goals for psoriasis treatment have changed
drastically in the last 15 years. More small molecules and
biologics for psoriasis are in the pipeline. Dermatologists
will need a greater facility working with multiple drugs
and managing more complex pharmacological
treatments; patient expectations about therapeutic goals
and product safety must evolve as well. In terms of
systemic treatments for psoriasis, we are on the cusp of
a renaissance.
Psoriatic Arthritis: 
Key Developments in 2014
The prevalence of psoriatic arthritis in psoriasis
patients appears to be about 30 percent based on the
PREPARE study, of whom about 41 percent had not been
previously diagnosed with psoriatic arthritis.49
Extrapolated from psoriasis rates, the overall prevalence
of psoriatic arthritis may be as high as one percents of
the population.50 In patients with both psoriasis and
psoriatic arthritis, the cutaneous symptoms may precede
musculoskeletal symptoms by 10 years.51 Since joint
damage may occur within two years of disease onset,52
timely and accurate diagnosis and prompt treatment are
essential to maintain optimal function. Yet in a large,
population-based survey of patients with psoriasis and/or
psoriatic arthritis in Europe and North American
(n=3,426 of whom 712 had psoriatic arthritis), the
average time between onset of psoriatic arthritis signs
and symptoms and its appropriate diagnosis was five
years.53 Of those with known psoriatic arthritis, 15
percent in North America and 22 percent in Europe had
not seen a healthcare provider in the past year for that
condition. Only about a third of patients (38% in North
America and 37% in Europe) reported their psoriatic
arthritis was most often treated by a rheumatologist.53
Thus, there is an urgent need to shorten the time from
onset of symptoms to diagnosis and treatment of
psoriatic arthritis, because delayed diagnosis has been
associated with poorer outcomes.54
Polyarticular disease in psoriatic arthritis can be as
severe as rheumatoid arthritis, although it is often not
treated as aggressively. Powerful new treatments for
psoriatic arthritis are available, although 31 percent of
those with known psoriatic arthritis receive only topical
treatments and another 28 percent receive no treatment
at all.53
A number of classification systems exist to help
categorize psoriatic arthritis symptoms. The CASPAR
Classification System requires that a patient must
present with inflammatory articular disease (joint, spine,
or entheseal) and have a score of ≥3 on the following:
current psoriasis (score 2), family history of psoriasis, RF
negativity, current dactylitis or history of dactylitis
documented by a rheumatologist, radiographic evidence
of juxta-articular new bone formation, or typical psoriatic
nail dystrophy.55 The CASPAR Classification System is
91-percent sensitive and 99-percent specific for psoriatic
arthritis, including early disease, and across various
populations. Other screening tools include Psoriatic
Arthritis Screening and Evaluation (PASE), Toronto
Psoriatic Arthritis Screening Questionnaire (ToPAS),
and Psoriasis Epidemiology Screening Tool (PEST). The
Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) has published treatment
recommendations for psoriatic arthritis that are based on
a multidisciplinary paradigm.56
TNF-inhibitors have revolutionized the treatment of
psoriatic arthritis. In this regard, it is important to note
that biosimilars will also change how psoriatic arthritis is
treated.57 Biosimilars have been studied in diseases such
as rheumatoid arthritis, but not psoriatic arthritis, yet in
Europe, biosimilar approval encompassed psoriatic
arthritis, although they had not been tested in this
Figure 2. The emerging treatment paradigm for psoriasis versus the
older stepwise model.
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setting.58 This may very well have less to do with medical
science and more to do with healthcare economics, but
dermatologists in North America may soon encounter
biosimilars arriving here in similar fashion.59
In determining appropriate dosing for TNF-inhibitors,
the relationship of trough serum biologic concentrations
and therapeutic response has been explored. In a
prospective study of 103 consecutive psoriatic arthritis
patients, patients were treated with adalimumab and
their serum concentrations of antidrug antibodies (ADA)
were recorded.60 ADA concentrations were significantly
lower at 28 and 52 weeks in patients with detectable
ADA levels compared to those with no detectable ADA
levels. Patients with detectable ADA had lower
adalimumab concentrations and significantly poorer
outcomes compared to patients in whom no ADA could
be detected.
An important therapeutic topic with possible public
health and even political ramifications involves treatment
discontinuation for patients in remission. For example, in
a study of 76 psoriatic arthritis patients, 53 remitted and
had their doses halved; at 29 months, 88.6 percent were
still in remission.61 However, in a prospective
observational study of 26 psoriatic arthritis patients
treated with methotrexate or a TNF-inhibitor, treatment
was stopped upon remission and 77 percent experience
rapid flares (mean 74.5±52 days).62 Should a decision be
reached to taper or discontinue biologic therapy upon
achievement of treatment goals, the clinical team should
develop a tapering plan, establish metrics for clinical
success and failure, and account for motivations for
discontinuing therapy (for example, whether this
strategy was a payer-drive decision or a patient
preference).63,64 It is unclear how to identify the subset of
patients in remission who will do well even after
treatment stops, and it is also not established if and for
how long they should be followed once treatment is
discontinued.
In FUTURE1, a placebo-controlled study of 606
psoriatic arthritis patients treated with intravenous (IV)
secukinumab 10mg/kg up to a maximum dose of 150mg,
IV secukinumab 10mg/kg up to a maximum dose of
75mg, or placebo, 50.0 and 50.5 percent of the IV
secukinumab 150 and 75mg maximum groups,
respectively, met the study’s primary endpoint of an
ARC20 score (placebo 17.3%) at 24 weeks. Scores for
ARC50 were 34.7, 30.7, and 7.4 percent, respectively,
and scores for ARC70 were 18.8, 16.8, and 2.0 percent,
respectively.65 The FUTURE1 study then grouped
patients by prior exposure to a TNF-inhibitor and found
that TNF-inhibitor-naïve patients overall had better
results than those who had previously taken TNF
inhibitors. Futhermore, PASI scores were good in the
FUTURE1 study with 76.9 and 65.7 percent of patients
taking IV secukinumab up to 150 or 75mg, respectively,
achieving PASI75 scores and 59.3 and 48.1 percent,
respectively, achieving PASI90.65
Ustekinumab is increasingly prescribed for psoriatic
arthritis, with the unexpected finding in the PSUMMIT 1
and 2 studies that it reduced joint damage as evidenced
in radiographs of hands and feet.66
The PALACE1 studies evaluated apremilast in
psoriatic arthritis patients and found results for
aprimelast 30mg twice daily, 20mg twice daily, and
placebo were 45, 36, and 13 percent, respectively, for
ARC20; 22, 16, and 4 percent, respectively, for ARC50;
and 12, 6, and 1 percent, respectively, for ARC70.67 Data
from that study and the subsequent PALACE2 and
PALACE3 studies, found adverse events with apremilast
occurred in about a quarter of all patients, with nausea
and diarrhea the most frequently reported side effects.
Unintentional weight loss of up to 5 or 10 percent of body
weight occurred in about 10 percent of patients.
Depression as a possible treatment-emergent adverse
event occurred in one percent of aprimelast and 0.8
percent of placebo patients.68
Update on Psoriasis Comorbidities
There is a large and growing body of literature linking
psoriasis to metabolic syndrome, atherosclerosis, and
myocardial infarction.69–73 Obesity, an independent risk
factor for psoriasis, has been associated with more
severe psoriasis. Psoriasis is further associated with
diabetes, major cardiovascular events, and chronic
kidney disease independent of the traditional risk factors
for these conditions.69,70,74 Although these comorbidities
represent diverse phenotypes, they share the following
pathological elements: chronic inflammation,
angiogenesis, oxidative stress, and selected genetic
components. Severe psoriasis is associated with an
increased risk of mortality that culminates in
approximately five years of life lost.75,76 
Emerging data has compared cardiometabolic
outcomes in psoriasis patients treated with systemic
agents and phototherapy to rheumatoid arthritis patients
receiving disease-modifying antirheumatic drugs
(DMARDs). Psoriasis is associated with an increased risk
of diabetes that is independent of traditional risk factors,
whereas RA is not associated with diabetes.77 Alarmingly,
emerging pediatric data suggest that metabolic
syndrome develops early. The prevalence of metabolic
syndrome in pediatric psoriasis patients was found in one
study to be 30 versus 7.4 percent control (p<0.05).78
Moreover, the risk of cardiovascular mortality and all
cause mortality in moderate-to-severe psoriasis is quite
similar to the risk of these outcomes in patients with
moderate-to-severe RA.79
The risk of cardiometabolic disease is so pronounced
in patients with more severe psoriasis that patients with
severe psoriasis are 30 times more likely to experience a
MACE attributable to psoriasis than to develop a
melanoma. Their 10-year risk of a MACE attributable to
psoriasis is six percent, and psoriasis reduces their life
expectancy by five years.76,80–83
In a KC-Tie2 psoriasis skin-specific murine skin
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model, aortic inflammation and thrombosis could be
modeled.84,85 Skin-specific inflammation may drive
vascular disease with aortic inflammation associated with
psoriasis equivalent to about 10 years of aging.
Despite a robust body of literature in support of the
metabolic and cardiovascular risks associated with
psoriasis, particularly in its more severe manifestation,
clinicians may under-screen and under-manage these
risks in their psoriasis patients. For example, psoriasis
patients are at elevated risk for hypertension and the
prevalence of uncontrolled hypertension (among
patients with high blood pressure) is 51.6 percent of
patients in the general population, 53.9 percent for
psoriasis patients in general, and 59.5 percent of severe
psoriasis patients.86 Yet dermatologists do not routinely
screen severe psoriasis patients for hypertension.87
Whether dermatologists should treat psoriasis as
aggressively as possible to reduce cardiovascular risk
remains an open question, and the relationship between
greater psoriasis control and improved cardiovascular
outcomes is the focus of several planned and ongoing
studies. Some observational data suggest that
methotrexate and TNF inhibitors for psoriasis may
reduce cardiovascular events, but data do not exist for
other treatment modalities.88–91
The following emerging comorbidities associated with
psoriasis may seem unexpected: sleep apnea,
nonalcoholic steatohepatitis (NASH), chronic
obstructive pulmonary disease (COPD), infections,
chronic and end-stage renal disease, and peptic
ulcers.92–96 Patients with moderate-to-severe psoriasis
have a twofold risk of chronic kidney disease and a
fourfold risk of dialysis, independent of hypertension and
diabetes.97 In fact, severe psoriasis patients are at a
greater risk for chronic kidney disease than patients with
diabetes and hypertension.97 Psoriasis is also associated
with mental health conditions, such as anxiety,
depression, and suicidal ideation.98 Restless leg
syndrome and atrial fibrillation have recently been
implicated as potential psoriasis comorbidities.99,100
These findings challenge the old notion that psoriasis
is “just a skin disease.” Comorbidity research suggests
that psoriasis is part of a larger systemic disease that
confers substantial risk. Clinicians treating psoriasis
patients should expand their standard screenings to
include regular evaluations for hypertension, diabetes,
and cardiovascular risks, and patients should be
encouraged to keep up with regular cancer screenings,
especially when considering immune modulating
treatments. Clinicians should screen for infections, and
human immunodeficiency virus (HIV) screenings should
be performed in those with severe psoriasis. Psoriasis
patients undergoing immune suppressive treatment
should be vaccinated against influenza, pneumonia, and
hepatitis B, and young psoriasis patients (ages 9–26)
should be vaccinated against the human papilloma virus
(HPV).101 Zoster vaccine should also be considered,
especially in older patients, but it is a live vaccine and
thus should be given prior to initiating an immune
suppressive treatment. Finally, it is well-known that a
large subset of psoriasis patients will develop psoriatic
arthritis. Psoriasis patients should be regularly screened
for psoriatic arthritis and educated about its symptoms.
Cutaneous Oncology 
Cutaneous Manifestations of Systemic
Malignancy and Disease
Systemic malignancies often have a cutaneous
presentation, presenting dermatologists with the unique
opportunity to identify early clinical presentations of
paraneoplastic dermatoses as well as other skin
conditions associated with systemic disease processes.
Disease categorization should be based on pathology. A
categorization scheme might include papulosquamous
disorders, interface dermatitides, reactive erythemas,
neutrophilic dermatoses, dermal proliferative disorders,
deposition disorders, and other (miscellaneous)
dermatoses.
Papulosquamous disorders may routinely be seen in
clinical practice, although there are also rare forms, such
as acanthosis nigricans, acquired ichthyosis, tripe palms,
Leser-Trélat sign, and acrokeratosis paraneoplastica
(also known as Bazex syndrome). Interface dermatitides
include dermatomyositis, paraneoplastic derma-
tomyositis, and paraneoplastic pemphigus. Reactive
erythemas and neutrophilic dermatoses include
erythema gyratum repens, necrolytic migratory
erythema, Sweet’s Syndrome, and pyoderma
gangrenosum. Sweet’s Syndrome is relatively common,
but the underlying malignancies associated with it are
less well-known. Dermal processes infiltrate the skin, but
the following conditions are rarely seen in the clinic:
multicentric reticulohitiocytosis, necrobiotic xantho-
granuloma, scleromyxedema, cutaneous amyloidosis,
and hypertrichosis lanuginosa acquisita. Certain more
common dermatologic conditions suggest systemic
disease and deserve greater elucidation. 
Acquired ichthyosis. It is not unusual to treat
ichthyosis in clinical practice, but a sudden onset of a
new case in elderly patients (>50 years), particularly
with a distribution pattern similar to ichthyosis vulgaris
(that is, sparing palms, soles, folds, or flexures) suggests
either an inflammatory response or an underlying
malignancy. Acquired ichthyosis may present before or
after a cancer diagnosis. About 70 to 80 percent of
cancer associated with acquired ichthyosis is Hodgkin’s
lymphoma. Acquired ichthyosis may also occur in non-
Hodgkin’s lymphoma, multiple myelomas, and
leukemia.102
Acanthosis nigricans. Acanthosis nigricans lesions
may appear on the neck, axillae, groin, hands, feet,
abdomen, nipples, or lips. They are associated with a
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variety of malignancies, including gastric, esophageal,
ovarian, endometrial, gallbladder, lung, and bladder
cancers, nearly all of which are adenocarcinomas and 70
to 90 percent are intra-abdominal (50–60% gastric).
Acanthosis nigricans in conjunction with tripe palms is
most typically associated with gastric cancers.
Unfortunately, cancer is usually well-established by the
time cutaneous signs appear. Successful treatment of the
cancer may result in resolution of the skin lesion.103,104
Tripe palms. Although not commonly seen in
clinical practice, tripe palms have an association with
lung cancer. Tripe palms typically present either slightly
before or around the same time as tumor diagnosis.
When tripe palms occur together with acanthosis
nigricans, they are associated with gastric tumors.105
Acrokeratosis paraneoplastica (Bazex
syndrome). Older patients with no history of skin
disease who present with sudden-onset psoriasis-like
plaques may benefit from a biopsy, because what appears
as psoriasis may, in fact, be psoriasiform epidermal
hyperplasia, which will not respond to the psoriasis
treatments. Untreated psoriasiform epidermal hyper-
plasia may appear on palmar surfaces instead of the
dorsal surfaces more typical of psoriasis. A typical
presentation involves symmetrically distributed lesions
over hands, feet, knees, nails, elbows, and ears. The
three clinical stages of the disease are:
•   Erythrosquamous eruption that typically involves
fingers and toes and may spread to nails
•   Violaceous keratoderma on lateral aspects of
fingers and toes
•   Eventual involvement of trunk, extremities, and
scalp.
Bazex syndrome is most commonly associated with
squamous cell carcinoma of the aerodigestive tract, but
also with adenocarcinoma. Most skin conditions (60%)
will occur a year before the tumor is diagnosed, but in
about 20 percent of cases the tumor and the skin
condition appear at the same time. Since the cutaneous
condition often appears before the tumor is detectable,
Bazex syndrome offers the dermatologist a “window of
opportunity” to refer the patient for timely and
potentially life-saving treatment. Bazex syndrome may
resolve when the tumor is irradiated.102
Scleromyxedema. Scleromyxedema is
characterized by an abrupt onset of waxy, erythemous
skin-colored papules and nodules, sometimes in linear
distribution, on the face, neck, chest, and limbs.106 A
biopsy may be needed to differentiate scleromyxedema
from plaque-like cutaneous mucinosis.
Dermatomyositis. Idiopathic dermatomyositis is a
prevalent skin condition, and it may be associated with
malignancies in elderly patients (>50 years). The skin
condition precedes the malignancy; tumors are typically
diagnosed in a year. Older female patients with sudden
dermatomyositis are predisposed to ovarian carcinoma, a
cancer that otherwise often defies early detection. Thus,
this skin condition may offer another “window of
opportunity” for dermatologists. In many cases,
treatment of the malignancy helps to resolve the skin
changes. 102
Paraneoplastic pemphigus. Paraneoplastic
pemphigus is often seen in clinical practice and may
include lip erosion, papules on the tongue, and
involvement of the ocular orbits. The typical
presentation involves pruritic polymorphous papules and
patches on the trunk, leading to mucosal erosions, which
may include the conjunctiva and genitalia. Severe
palmoplantar involvement may occur with painful
erosions at the fingertips. This condition typically afflicts
the elderly, with an average age of onset of 59 years. In
75 percent of cases, this cutaneous condition may be
associated with lymphoproliferative diseases (42% non-
Hodgkin’s lymphoma, 29% chronic lymphocytic
leukemia, and Castleman’s disease). The skin condition
will not resolve if there is underlying malignancy, even if
it is aggressively treated.102,107
Sweet’s syndrome. Sweet’s syndrome is a
neutrophilic dermatosis with cutaneous and often painful
lesions. It may be associated with underlying malignancy,
infection, systemic inflammatory disorders, or the use of
certain medications. When Sweet’s syndrome is
associated with cancer, it is typically a hematologic
cancer, but it may also be associated with solid tumors in
the genitourinary tract. In a retrospective study of 77
Sweet’s syndrome patients evaluated at the Mayo Clinic
from 1992 to 2010, 35 percent had a malignancy.108 Of
malignancy-associated Sweet’s syndrome patients, about
40 percent will be diagnosed with cancer within a
month.102,109 Patients with Sweet’s syndrome should be
screened for malignancies (blood counts, peripheral
smear) and biopsies repeated, if needed.
Sweet’s syndrome has also been associated with
chronic inflammatory conditions, such as inflammatory
bowel diseases (including Crohn’s disease) and
ulcerative colitis (UC).110 In contrast to UC and Sweet’s
syndrome, Crohn’s disease with Sweet’s syndrome may
skip areas on the mucosal wall. In fact, Crohn’s disease
with Sweet’s syndrome will present with lesions typically
in the perianal region in only about 10 to 30 percent of
patients. These lesions or fistulae may be ulcerated and
show a granulomatous pattern of inflammation. The
lymph nodes may be involved and there may be other
systemic sequelae. Metastatic Crohn’s disease is rare, but
when it presents, its lesions may mimic those of
erythema nodosum. Granulomatous colitis occurs
around colostomy sites; this may lead to metastatic or
localized Crohn’s disease.
In general, Crohn’s disease is associated with greater
cutaneous symptomology than UC. UC presents with
diffuse colon-rectal inflammation that is more likely to
lead to serious complications, such as colon cancer, than
Crohn’s disease. UC patients typically present with more
overt and more severe gastrointestinal complaints,
including bloody diarrhea, compared to patients with
Crohn’s disease. 
The pattern of inflammation with UC is usually
observable throughout the colon, starting at the rectum
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and spreading proximally. With a typical onset in early
adulthood, UC may be linked to underlying pathology, for
example, inflammatory bowel disease. Cutaneous
manifestations associated with ulcerative colitis include
erythema nodosum, pyoderma gangrenosum, apthous
stomatitis, aseptic pustular eruptions, and pyoderma
vegetans (rare).111,112 Apthous stomatitis associated with
either UC or Crohn’s disease may be substantially larger,
more painful, and more challenging to treat than other
forms of apthous stomatitis. Apthous stomatitis will flare
or remit based on bowel involvement. Erythema
nodosum may occur in patients with either Crohn’s
disease or UC (more common). Erythema nodosum is
the most frequently observed skin manifestation of
bowel disease in pediatric patients. Systemic steroid
treatment may be appropriate with nonsteroidal anti-
inflammatory drugs (NSAIDs) for pain control.
Pyoderma gangrenosum is three times more
common in UC than Crohn’s disease; about half of
patients with pyoderma gangrenosum have UC. It usually
initiates with a pustule that becomes a nodule, ulcerates,
and then produces exudate. Pyoderma gangrenosum
may appear at any site on the body, but favors acral sites.
Treatment for pyoderma gangrenosum includes systemic
steroids (such as prednisone 1–2mg/kg per day) along
with cleaning, but not debriding the lesions. Patients can
then be transitioned to dapsone, sulfasalazine,
methotrexate, and other drugs, including biologics.
Biologics may be able to address both the pyoderma
gangrenosum and gastrointestinal symptoms.113 Healed
pyoderma gangrenosum may scar with a unique almost
“shiny” appearance.114
Pyostomatitis vegetans. Pyostomatitis vegetans
involves annular, pustular skin lesions with a “snail track”
appearance, which may accompany, precede, or follow
extensive vegetating oral disease. The cutaneous and
oral lesions are manifestations of the same disease and
are associated with UC.115
Erythema gyratum repens. In this rare condition,
patients present with polycyclic, geometric, and arciform
plaques with a “wood grain” appearance. Erythema
gyratum repens occurs twice as often in men as women
and is one of the most specific paraneoplastic cutaneous
conditions, in that it has an 82-percent association with
malignancy, most commonly bronchial cancer, followed
by esophageal cancer. In 80 percent of cases, cutaneous
manifestations precede the tumor by as much as two
years, offering dermatologists a “window of opportunity”
for early detection.116 This rare, but clinically distinctive,
skin condition may sometimes be associated with drug
intake.117
Necrolytic migratory erythema. Necrolytic
migratory erythema may be considered an obligatory
paraneoplastic syndrome, usually associated with a
glucagon-secreting tumor of the alpha-islet cells of the
pancreas.118 Cutaneous symptoms, which typically
TABLE 2. The ILDS treatment guidelines for AK used this verbiage in its recommendations. Note that strength of 
recommendation and expert consensus (implications) are two different categories and not necessarily equivalent
STRENGTH WORDING SYMBOL IMPLICATIONS
Strong recommendation
FOR the use of 
intervention
“We recommend…” ↑↑
We believe that all or almost all informed people would make that
choice. Clinicians will have to spend less time on the process of
decision making and may devote that time to 
overcome barriers to implementation and adherence. In most clin-
ical situations, the recommendation may be adopted as policy.
Weak recommendation
FOR the use of 
intervention
“We suggest…” ↑
We believe that most informed people would make that choice,
but a substantial number would not. Clinicians and healthcare
providers will need to devote more time on the process of share
decision making. Policy makers will have to involve many 
stakeholders and policy making requires substantial debate.
No recommendation with
respect to an intervention
“We cannot make a recommen-
dation with respect to…” 0
At the moment, a recommendation in favor or against an 
intervention cannot be made due to certain reasons, e.g., no 
evidence data available, conflicting outcomes, etc.
Weak recommendation
AGAINST the use of an
intervention
“We suggest not to…” ↓ We believe that most informed people would make a choiceagainst that intervention, but a substantial number would not.
Strong recommendation
AGAINST the use of an
intervention
“We recommend not to…” ↓↓
We believe that all or almost all informed people would make a
choice against that intervention. This recommendation can be
adopted as a policy in most clinical situations.
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precede the tumor, include erythematous scaly lesions
which typically appear on the perineum, distal
extremities, lower abdomen, and face. The clinical
syndrome includes diabetes, macroglossia, anemia,
unintentional weight loss, and diarrhea. While the
cutaneous symptoms usually appear in advance of the
tumor, patients often do not present for medical care
until their symptoms progress. 118
Cutaneous metastases. The most common sites
for cutaneous metastases are the trunk and scalp, and
the site is often close to the site of the primary tumor.
For men, the most common underlying disease is lung
cancer followed by colon carcinoma; for women, it is
breast cancer and colon carcinoma. The overall
incidence of such cutaneous metastases is low (about
2–6%), and it may be considered in general as a poor
prognostic indicator.119
The International League of Dermatological
Societies Guidelines for Treatment of 
Actinic Keratosis
Spearheaded by Dr. Eggert Stockfleth, Dr. Alexander
Nast, and Ricardo Werner, the International League of
Dermatological Societies (ILDS) guidelines were created
by an expert panel of 15 dermatologists, three
dermatopathologists (histopathologists), and one patient,
with the goals of advancing a more widely accepted
definition of actinic keratosis (AK), raising awareness
among other disciplines about AK (for example, primary
care physicians, internists, Ob-Gyn, plastic and ENT
surgeons), publishing systematic assessments of the
safety and efficacy of the available treatments, and
improving the quality of care, including reducing the
number of patients whose AKs progress to invasive
squamous cell carcinomas (SCCs). The Cochrane review
of AK interventions was evaluated,120 updated, and the
Cochrane “risk of bias” tool was applied followed by use
of the evidence-based GRADE system. Evidence was
rigorously assessed using a forest plot. Results from the
literature were presented to the expert committee, who,
in turn, consulted in an online conference to offer their
treatment recommendations. Recommendations were
based on the scheme presented in Table 2. The steering
committee drafted the recommendations, which were
reviewed internally by the expert committee members
and then subjected to an external review. The finalized
manuscript has been submitted for publication, with the
hope that this will become an international guideline. 
As an example, consider a patient with a single AK.
More than 75 percent suggested treatment with 0.5%
fluorouracil and gave it a ↑ recommendation. A patient
with multiple AK lesions or field cancerization ≥50
percent was given a ↑↑ recommendation for 0.5%
fluorouracil. 
As with any guidelines, it is important that we
recognize the value of professional expertise, clinical
judgment, and individualized care. Guidelines should not
be taken as inflexible mandates, but as guidance based
on the best available evidence to date to aid clinical
judgment.
New and Novel Uses for “Field Therapies”
AK is often considered strictly as a field disease and
is treated with field-directed therapies. However,
subclinical AK may present with cells genetically
similar to AK and SCC.121 Advanced imaging technology,
such as cross-polarized light, fluorescence, and
dermoscopy, may be helpful in identifying different
types of subclinical AK lesions. Reflectance confocal
microscopy and high-definition optical coherence
tomography can provide high-resolution skin imaging
and have the capacity to detect subclinical lesions
noninvasively.122 The toolkit is robust and useful, but
these technologies have some disadvantages as well,
particularly in terms of cost.
Photodynamic Therapy 
Photodynamic therapy (PDT) requires oxygen, a
photosensitizer, and an activating wavelength of light.
Cutaneous application of pro-drugs 5-aminolevulinic
acid (5-ALA) or methylaminolevulinic acid (MAL; no
longer commercially available in the United States, but
widely used in other parts of the world) bypasses the
rate limiting step in the heme synthesis pathway. This
results in the preferential accumulation of the
photosensitizer protoporphyrin IX (PpIX) within AKs,
which can be targeted with activating wavelengths of
blue or red light.
The pivotal phase 3 ALA PDT trial utilized a 14- to
18-hour ALA incubation period in order to maximize
PpIX buildup within AKs, which peaks at approximately
12 hours. This prolonged incubation is impractical for the
practicing clinician and patient. In a recent phase 2 study
evaluating shorter incubation periods, patients were
divided into the following five groups:
•   Group 1: Broad area (BA) application of ALA one
hour prior to blue light
•   Group 2: BA application of ALA two hours prior to
blue light
•   Group 3: BA application of ALA three hours prior
to blue light
•   Group 4: Spot application of ALA two hours prior
to blue light
•   Group 5: Vehicle group.
Study results found that the one-, two-, and three-
hour incubation periods resulted in 35- to 57-percent
clearance at eight weeks, 78 to 80 percent at 12 weeks,
and 64 to 75 percent at 24 weeks, respectively,
demonstrating that multiple treatments with shorter
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incubation times per treatment were effective. To
achieve around 80-percent clearance, at least two of
these shorter incubation treatments are needed at least
eight weeks apart. 
Patient discomfort during PDT remains an
important issue, with more than 60 percent of patients
in the previously mentioned short incubation study
reporting moderate-to-severe pain during treatment. A
new approach employing 30 minutes of MAL incubation
prior to 1.5 to 2.5 hours of exposure to daylight, which
serves as the activating wavelength of light, has vastly
improved tolerability while achieving individual AK
lesion clearance rates of approximately 75 percent.123 In
a report on three clinical studies, 92 percent of
daylight-mediated PDT patients reported mild to no
pain (defined as 0–3 on a 10-point analog scale), 7.5
percent said they had moderate pain (score 4–7), and
one patient reported severe pain (8–10). There was no
correlation between pain scores and efficacy.123
Unfortunately, these promising results are subject to
variations in seasonal weather patterns and hence
ambient activating light, so efforts were made to
develop an indoor form of painless PDT (George
Martin, MD, personal experience, submitted for
publication). The concept involved applying ALA to the
patient’s face about 15 minutes before the patient was
exposed to one hour of standard blue light (BLU-U,
Dusa Pharmaceuticals, Inc.) light, reversing the old
paradigm of long incubation with short light exposure.
Using a split-face study, painless indoor PDT (15-
minute incubation/60-minute blue light) was compared
to standard PDT (75-minute incubation, 1000-second
blue light) in three patients. Both treatments were
similarly effective and reduced AK count around 50
percent (painless indoor PDT had 27 AK lesions at
baseline, 13 post-treatment, 52% reduction; standard
PDT had a baseline count of 32 AKs, 18 post-treatment,
44% reduction). Pain scores on a scale of 0 to 5 (with 0
being no pain) showed the “painless” indoor PDT lived
up to its name with a score of 0 (range 0–0) while
standard PDT had an average pain score of 3.5 (range
3–4). While large, randomized, controlled trials are
needed for this new painless PDT treatment model,
initial evidence provided by this split-face study and
experience in more than 100 patients utilizing the
protocol as monotherapy or in conjunction with
pretreatments using 5-fluorouracil or imiquimod
suggests this type of therapy can be readily reproduced
in the clinic.
Most AK studies compare treatments to a placebo
rather than head-to-head. A recent meta-analysis (25
studies, n=5,562 total patients) attempted to evaluate
the most effective AK treatments by comparing them
directly using a complicated statistical model.124 With the
exception of diclofenac 3%, all treatment options
achieved at least 40-percent clearance and only one
treatment offered 70-percent clearance (ALA-PDT gel).
Thus, it is reasonable to say that many AK treatments are
effective, but ALA-PDT seems superior.
There is a rationale for using PDT to prevent basal
cell carcinoma (BCC), which can develop in older
patients treated with X-ray therapy for acne, who are at
risk for developing numerous facial BCC, or middle-aged
patients with a history of multiple facial BCC. Thus,
“preventative PDT” might decrease the risk of further
BCC development. In case reports on six patients with
basal-cell nevus syndrome, 20% ALA was applied to up
to 22 percent of the body surface area for 24 hours under
occlusion and then patients were exposed to red light for
one to three treatments.125 The decision to use red rather
than blue light was based on the idea that the longer
wavelength of red light would penetrate better
(penetration is about 2.0mm with blue light and ≥5mm
with red). Responses were durable up to six years (two
patients had clearance for an average of five years). This
study suggests that PDT destroys clinically visible BCC
but also subclinical lesions as well. Localized PDT
induces a systemic immune response involving the
production of antibodies to HIP1 (BCC-specific associate
antigen). In a study comparing PDT to surgery for BCC,
these antibodies were produced within 7 to 10 days post
PDT, but not in the surgical group.126 This supports the
argument favoring preventative PDT therapy for patients
predisposed toward multiple BCC.
Figure 3. The histology of certain invasive forms of high-risk basal cell carcinoma.
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Imiquimod
Most patients see AK lesions partially or completely
cleared following a 2 week on-2 week off-2 week on daily
application of 3.75% imiquimod (IM) to the face and
scalp.127 An alternative and effective approach to limiting
downtime and maintaining long-term efficacy involves
daily application of 3.75% IM to the face for seven days
followed by a two-week rest period and then continuing
with a once-weekly application for over a year (George
Martin, MD, unpublished observatioin).
Ingenol Mebutate 0.015% and 0.05%
Ingenol mebutate has dual mechanisms of action—it
causes controlled cell death within a matter of hours and
an  IL-8 neutrophilic immune response over the course of
the next days. Phase 3 trials treating only areas about
25cm2 have resulted in good safety data with no scarring
or hyperpigmentation issues.128 Since patients must self-
administer this agent, it is very important for clinicians to
set realistic expectations. The initiation of ingenol
mebutate over larger areas than the approved protocol,
while apparently safe and efficacious, may result in a
temporary, but marked, exacerbation of symptoms.
Patients should be educated to expect results along the
lines of a “bad sunburn” particularly if large areas of the
chest are treated, and be provided analgesics, if
necessary.
Combination therapy. Ingenol mebutate may be
combined with cryosurgery for treating AK.129,130 In these
studies, combination therapy was more effective than
cryosurgery alone at 11 weeks (60.5 vs. 49.4%,
respectively) and at 52 weeks (30.5 vs. 18.5%). Thus,
these cryosurgery results are not as effective in clearing
AKs as combination therapy results.
High-risk Basal Cell Carcinoma and Squamous
Cell Carcinoma: Recognition and Treatment
Basal cell carcinoma. Basal cell carcinoma (BCC)
is the most common cancer in humans, and its incidence
is on the rise. Although there are no official registries
maintained, it is estimated that 2 to 4 million new cases
occur per year in the United States.131 The incidence
increases with age (median age of patient is 68 years, but
younger patients are increasingly affected) and a
disproportionate relative increase has been noted in
women. Skin type and exposure to UV radiation remain
the predominant risk factors leading to a mutation of the
PTCH gene. 
Certain BCC may be considered a low-risk cancer. In
these cases, the histology of BCC is superficial, nodular,
small in size, and with well-defined margins. Most BCC
lesions appear on the trunk and extremities, rather than
the face. These include superficial BCC, BCC with
atypical basaloid islands, and micronodular BCC. When
dealing with these BCC subtypes, clinicians should bear
in mind that biopsies may be too small to be
representative of the cancer. A “thin shave” might miss
deeper growth in certain nodular or micronodular forms
of BCC. Furthermore, there can be “sampling errors” in
that the sample may be taken from less aggressive
regions of the cancer.
High-risk BCC exhibits an aggressive growth pattern,
frequently recurs, tends to be larger, and may appear on
Figure 4. The classical appearance of a keratoacanthoma. Note the
endophytic, crateriform architecture, hyperkeratotic debris, and
squamous islands with the glassy atypia to the keratinocytes. 
Figure 5. Squamous cell carcinoma in situ with follicular extension
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the mask or “H-zone” of the face along the embryonic
fusion planes. High-risk BCC often exhibits ill-defined
clinical margins and may be associated with
immunosuppression. It is not unusual to see these high-
risk BCC occur at sites of prior radiation (such as the
sites for X-ray therapy in acne patients). The histology of
invasive forms of BCC appears in Figure 3. Tumor size
may help define risk—high-risk growths may be
considered those >6mm in the mask area of the face;
>1cm on cheek, forehead, scalp, or neck; and >2cm on
the trunk or extremities.
When treating patients with BCC, dermatologists
should consider patients holistically, recognizing that not
all patients are appropriate candidates for aggressive
treatments. Since significant morbidity may be involved,
all likely treatment options should be evaluated and
discussed with the patient. In this connection, it should
be noted there are no absolute indications for Mohs
surgery. 
Squamous cell carcinoma. Squamous cell
carcinoma (SCC) is the second most common form of
cancer with over half a million new cases diagnosed each
year. Men are about twice as likely to be diagnosed with
SCC as women, and the incidence of SCC increases
sharply with advanced age. In fact, among patients over
80 years of age, skin cancer deaths are more likely to be
attributable to SCC than melanoma.131 Risks for
developing SCC include chronic, long-term exposure to
UV light; tanning; or ionizing radiation with a latency
period that may exceed 20 years. Organ transplant
recipients and other immunocompromised patients are
at increased risk. Certain strains of HPV may also be
considered risk factors along with exposure to certain
chemicals, nonhealing wounds, lupus, genetic
syndromes, and burns. In basic terms, anything that
causes skin cells to turn over at an accelerated rate will
increase the chance of replication errors and, in that way,
raise the risk of SCC. Surgical excision is the first-line
treatment for most forms of skin SCCs, but other
treatments are available as well.132
Certain in-situ SCC may be considered low risk,
such as Bowen’s disease or keratoacanthoma (Figure 4).
Most of these lesions may track down to the follicle
(Figure 5).
When treating these SCC lesions, curetting is helpful
before performing the first Mohs layer. In a small, but
significant subset, the curette will “dive” a bit deeper
than anticipated, will not “scoop out” cleanly, or will
encounter a gelatinous bottom. In such cases, a biopsy
may be conducted. Note that shave biopsies may not
detect poorly or moderately differentiated histology near
the base of the lesion. Histology may change as depth
increases. 
More invasive forms of SCC may occur in the ear, lip,
and genitalia. Poorly differentiated areas may require
greater scrutiny, in that atypical single cancer cells may
be “hiding” in areas of inflammation. Immunostains may
be necessary with poorly differentiated SCC; multiple
stains may be required to confirm spindle-cell SCC. The
histology of these more aggressive SCC may include
perineural invasion and they may be acantholytic,
adenoid squamous, or desmoplastic. Perineural
envelopment occurs when the SCC in the field, the
nerve, and the area around the nerve are surrounded by
keratinocytes. While not all SCCs are painful, perineural
involvement may be associated with pain and
paresthesia. These aggressive SCCs are characterized by
rapid growth and may track back through the foramen
into bone if left untreated. In advanced cases, the larger
cranial nerves may become involved.
Patient education is an important element in care of
the SCC. It is crucial that patients make the mental
connection between their “skin problem,” on the one
hand, and cancer on the other. 
Organ transplant recipients. There are more than
20,000 organ transplants performed each year in the
United States with approximately 140,000 organ
transplant recipients (OTRs) alive today. The
immunosuppressive pharmacological regimens taken by
OTRs increase their rates of malignancy, in particular
skin cancers.133 The relative risk increase for skin cancer
in OTRs is a 3.4-fold increase for melanoma, a tenfold
increase for BCC, and a 65-fold increase for SCC.
Further, the metastatic rate from SCC in OTRs is seven
percent and has been associated with a poor prognosis.
Among OTRs, risks are elevated for older patients (with
more cumulative UV exposure), longer duration of
immunosuppression, intensity of immunosuppression,
Fitzpatrick type I to III, significant history of UV
exposure, and the type of organ transplant. The risk is
greater for heart transplant patients, which reflects
differences in immune suppression. 
Treating OTRs with cutaneous cancers requires a
special level of expertise and highly individualized care.
Transplant patients must have a way to rapidly access
the clinical team, for example, with emergency phone
numbers. 
Metastatic SCC. High-risk SCC accounts for up to
2,500 deaths/year. When clinically detectable nodal
metastases occur, five-year survival is under 30 percent.
The treatment for metastatic SCC may involve “watchful
waiting,” adjuvant radiation, elective lymph node
dissection, and sentinel node biopsy. Patients must be
educated about the seriousness of this condition. For
example, if an initial procedure gives them early positive
results, patients should be counseled regarding the risk
of recurrence, what “metastases” means, and the
importance of surveillance.
Treatment options for BCC and SCC. There are
a variety of treatment options for patients with BCC or
SCC, which can be broadly categorized as surgical versus
nonsurgical and those that involve or do not involve
margin control. Among the nonsurgical options, one may
include radiation, PDT, 5-fluorouracil, and imiquimod.
Surgical options include curettage, cryosurgery, excision,
laser, and Mohs surgery. Cryosurgery may be particularly
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useful for superficial lesions, small lesions, or nodular
BCC, and should be considered in patients who may not
otherwise be good surgical candidates. Among the
potential drawbacks to cryosurgical approaches are slow
healing, hypopigmentation, and no margin control.
Curettage is an important procedure with several
clear advantages for the busy dermatology clinic; it can
be done quickly, the learning curve is short, only minimal
equipment (investment) is required, and it has a cure
rate of more than 90 percent. The main drawbacks to
curettage are that occasionally there is unpredictable
cosmesis, it may be associated with slower healing rates,
there is no margin control, and it is not suitable for high-
risk tumors. Curettage is indicated for superficial or
nodular, noninfiltrative, well-defined, primary, smaller,
low-risk BCC as well as for low-risk SCC, such as Bowen’s
superficial SCC. Curettage should not be used when
dealing with recurrent tumors or tumors with full
thickness into the subcutis. Curettage may be effectively
combined with electrodessication, cryosurgery, or
imiquimod. When curettage was combined with
electrodessication, the overall five-year recurrence rates
for treated BCC were 13 percent, with rates varying by
size (8.5% for 0–5mm, 15% for 6–9mm and 10–14mm,
20% for 15–19mm, and 26% for >20mm).134
The excision of BCC offers good margin control,
improved cosmesis, and more rapid healing with suture
closure. The potential disadvantages of BCC excision are
that the “breadloaf sectioning” may miss areas of the
tumor, there is a longer learning curve, and considerable
technical expertise is required for consistently
outstanding results. Excision can be a time-consuming
approach compared to other treatment options. For
excisions, 4mm or smaller BCC and 4 to 6mm SCC are
considered low-risk interventions, while interventions
involving BCC or SCC 6 to 10mm are high risk.
Incompletely excised BCC present clinicians with the
question whether to re-excise, in that tumor persistence
was shown in a retrospective study to be about 28
percent.135 Recurrence after excision with a positive
margin is about 35 percent; therefore, these are typically
either re-excised or treated with Mohs surgery. For a
select subset of patients, a watch-and-wait attitude may
be appropriate in that the immune response may clear
most residual cells, and the inflammatory process is
stopped when the lesion is closed.135 Low-risk parameters
include superficial or nodular subtypes, small size
(<1cm), and location not on the nose or ear. Thus,
most—but not all—patients should undergo re-excision
or Mohs surgery because of the high rate of tumor
persistence. Re-excision should also be considered for
high-risk tumors and for positive deep margins.
Mohs surgery remains the “gold standard” treatment
for tumor extirpation and is indicated for high-risk BCC.
High-risk parameters include recurrent nature, larger
tumors, aggressive histology, location, and incomplete
excision.136 The Mohs surgical procedure is unique in that
the surgeon serves as his or her own pathologist, the lab
is onsite, meticulous mapping and horizontal sectioning
are required, and the procedure looks at 100 percent of
the tumor. The main advantages of Mohs surgery is its
high cure rate, its tissue-sparing and structure-sparing
benefits, and the fact that immediate reconstruction can
be performed. The drawbacks to Mohs surgery are the
fact that experienced technical personnel are required to
support the procedures, which require additional
equipment. Mohs surgery can be expensive and may take
a comparatively long time. Recurrence rates for primary
BCC can be one percent for Mohs surgery, compared to
rates of 10 percent for excision and rates around 7 or 8
percent for electrodessication and curettage, radiation,
and cryosurgery.137
Disruptive Technologies for Skin Cancer:
Brachytherapy and Superficial Radiation
Electronic brachytherapy (EBX) and superficial
radiation will be important therapeutic options in the
future because of their impressive and durable cure rates
(87–100% at 2–5 years). Many cancers, including
prostate and cervical cancer, have been effectively
treated with EBX. In some instances EBX may be
combined with 30 to 40Gy high-dose radiation (HDR) to
optimize cure rates and possibly shorten the course of
therapy. EBX is recommended for use in nonmelanoma
skin cancers. In a study of 520 mostly BCC and SCC
patients over the course of 10 years, investigators
achieved a 92-percent cure rate. The local control rate
for HDR brachytherapy is between 93.7 and 97.5
percent.
HDR brachytherapy relies on iridium-192 and can be
performed, but EBX does not use any radioisotope. This
Figure 6. The HH pathway is active during normal embryonic 
development, but becomes inactive in adulthood. The PTCH and
SMO mutations in BCC pathogenesis activate the Hh pathway in 
certain adults.140
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means that EBX still uses the high-dose fractionation,
but is potentially safer with less collateral damage and
may even be more effective, in that the beam is flatter
and has less penumbra (less scatter). HDR
brachytherapy can be performed in a dermatology clinic
or physician’s office.
The workflow of HDR brachytherapy involves a
radiation oncologist, a radiation therapist, and a
physicist. A portable lead shield can be employed to
protect the patient rather than lead walls. The patient
enters the room and the machine is calibrated based on
the patient’s individual dosing parameters. A typical
treatment may take about 15 minutes. The course of
therapy is individualized, but often includes twice-
weekly sessions over a course of 8 to 12 treatments.
In a study of 187 patients (275 nonmelanoma skin
cancers), the surface applicator was 10, 20, 35, or 50mm
with a 2mm margin and a depth of 3mm (determined by
computed tomography for thick lesions).138 Patients were
treated twice weekly; dose fractionation was 5Gy for
eight fractions, resulting in a total of 40Gy. The study
population was 63 percent men, 97 percent Caucasian,
with a mean age of 73 years. Types of cancer treated
were predominantly BCC (n=159) and SCC (n=109).
With a mean follow-up of 10 months (range 1–28), no
recurrences and no adverse events ≥ grade 3 have been
observed. Mild grade 1 dermatitis occurred in 84 percent
of patients treated and 25 percent experienced grade 1
pruritus. The most common adverse event reported was
hypopigmentation, which occurred in 10.9 percent of 46
lesions at one year (all grade 1). Cosmesis at one year
was evaluated in 42 lesions, with 92.9 percent rated
“excellent.”138
Another treatment model is superficial radiation, in
which low-energy photons (rather than charged
particles) are delivered in a highly focused beam with the
ability to penetrate 0 to 1cm. Treatment duration is
about 90 seconds. The course of treatment (5 to 22
fractions) depends on the size, site, and type of tumor
being treated. A key advantage of superficial radiation is
that it can be performed in a doctor’s office or clinic,
providing a radiation therapist carries out the treatment.
In a retrospective, single-center study (n=1,715
histologically confirmed primary cutaneous BCC or
SCC), most patients had multiple tumors and could
select either Mohs surgery or superficial radiation
treatment (5 to 7 fractions for a total of 35Gy).139 The
recurrence rate for all tumors was 1.9 percent at two and
five percent at five years; recurrence specifically for SCC
was 0.8 percent at two years and 8.7 percent at five
years. Recurrence was most likely to occur in men and
tumors >2cm. Superficial radiation may be appropriate
for older, frail patients; those with larger tumors in
cosmetically sensitive areas, such as around the eyelids
or in areas that do not heal well, such as the shins; or in
patients taking blood thinners. 
Reimbursement for these therapies reflects the high
cost of the equipment and energy required and currently
relies on a temporary code that will sunset in 2017.
Superficial radiation treatments cost substantially more
than other treatments, raising a potential ethical issue.
However, it must be recognized that reimbursement is
typically more generous when a new technology emerges
in medicine, with the rationale that it incentivizes
practitioners to adopt new treatment modalities plus it
allows Medicare the opportunity to gather data. As the
technology becomes more entrenched and established,
reimbursement decreases. Reimbursement differentials
exist in other areas of medicine and even with Mohs
surgery codes where Mohs procedures may cost many
times more than traditional extirpation methods but can
still be ethically selected in certain cases. The use of
these emerging technologies may provide the patient
with a better informed consent, in that patients can
compare the proposed procedure to established
treatments with demonstrated cure rates. While our
healthcare system is moving toward cost-containment
strategies, there is simultaneously a drive toward more
patient-centered care paradigms. Skin cancer patients,
such as cosmetic dermatology patients, prefer less
invasive treatments and want to avoid needles, bandages,
blood, and long treatment courses as much as possible.
That is likely why EBX and superficial radiation are being
offered at more and more clinics today.
Mohs surgery and dermatology procedures have
already achieved high surgical cure rates. The evolution
of field treatment of nonmelanoma skin cancers include
outpatient and office-based procedures under local
anesthesia, aesthetic reconstruction, and scar revision
with laser technology. All of healthcare is evolving toward
personalized medicine through molecular targeting, and
in dermatology, minimally invasive radiation treatments
appears to be an interim step in that march toward
personalized medicine.
To advance these new treatment modalities,
dermatologists and Mohs surgeons should participate in
multidisciplinary brachytherapy societies.
Figure 7. Vismodegib binds to SMO and thus inhibits the 
HH signaling pathway.140,141
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Dermatologists should participate in multicenter clinical
trials and launch dermatologist-led specialty societies for
brachytherapy. These novel approaches should be
incorporated where appropriate into our skin cancer
treatment protocols. It would be useful to create a
paradigm for the area-under-the-dose-response curve
(AUC) for radiation therapies. There may be value in
developing a menu-type system of treatment hierarchies
and options with stronger “brands” and awareness of the
particular benefits and risks of various treatment
modalities. Within the next few years, dermatologists will
have five-year data for these treatments,
reimbursements will have decreased for EBX, and
private insurance may start to cover EBX, particularly if
there is patient-led demand for these procedures.
Treating Basal Cells with Drugs
The Hedgehog (Hh) signaling pathway is important
in human embryogenesis, with reduced or altogether
absent activity in adults. Aberrant Hh pathway signaling
can result in developmental abnormalities of the brain,
face, or midline.140 Hh pathways may be a factor in the
development of certain malignancies and, for that
reason, Hh inhibition may be an important treatment
strategy for cancer care.141 About 90 percent of sporadic
BCCs have a PTCH1 loss of heterozygosity and/or other
mutations in the PTCH1 genes, resulting in PTCH1
inactivation and activation of the Hh pathway. About 10
percent of sporadic BCCs have activating mutations in
the SMO gene, resulting in constitutively active SMO and
Hh pathway activation (Figure 6).142
Thus, aberrant Hh pathway activation has been
identified in both hereditary and sporadic BCCs. For
patients with hereditary BCCs, patients with basal cell
nevus syndrome (BCNS) carry germ-line hetereozygous
mutations in the PTCH1 gene that results in loss of
PTCH1 function; such individuals may be highly
predisposed to developing multiple BCCs. 142 On the other
hand, about 90 percent of sporadic BCCs have PTCH1
loss of heterozygosity, mutations in the PTCH1 gene, or
both, resulting in PTCH1 inactivation and Hh pathways
activation. About 10 percent of sporadic BCCs will
exhibit activating mutations in the SMO gene that result
in constitutively active SMO and Hh pathway
activation.140
Four agents are currently being evaluated for their
use in mediating Hh pathway signaling for the treatment
of BCC—vismodegib, sondigib/erismodegib (LDE225),
CUR61414, and saridegib (IPI-926). 
Vismodegib. Vismodegib was cleared for market
release in the United States in early 2012 by the FDA and
can be considered a first-in-class drug. It is indicated for
locally advanced BCC not amenable to surgery or
radiation and metastatic BCC (formerly treated with
cisplatin-based chemotherapeutic regimens).143 It is
contraindicated for use during pregnancy. The commonly
reported adverse events are muscle spasms, alopecia,
dysgeusia, weight loss, fatigue, anorexia, asymptomatic
hyponatremia, hyperglycemia, presyncope, pyelo-
nephritis, and amenorrhea.143 The recommended
vismodegib dose is 150mg orally once a day. 
The mechanism of action for vismodegib has been
described as SMO blockade, that is, it binds to SMO and
in that way blocks the Hh signaling pathway in cells with
either aberrant signaling driven by inactivating
mutations of PTCH or activating mutations of SMO
(Figure 7).
Vismodegib fits well into the dermatology clinic in
that it has similarities to biologics, methotrexate,
cyclosporine, and other drugs that require close clinical
supervision. Side effects are predictable, although some,
such as alopecia in women, may be treatment limiting.
Serious adverse events have occurred. Vismodegib is a
teratogen, and contraception is required for both men
and women taking this agent. It may be used
preoperatively to shrink a tumor or postoperatively. An
important treatment consideration is duration and
whether or not treatment might be interrupted (and
possibly biopsies scheduled periodically). The author
recommends treatment for 6 to 9 months with breaks for
most patients, although some may benefit from
treatment five days a week.
In an international, multicenter, two-cohort,
nonrandomized phase 2 vismodegib study in 96 advanced
BCC patients, patients were treated with 150mg of oral
vismodegib daily. Among patients with metastastic BCC
(n=33), the response rate was 30 percent (95%
confidence interval, range 16-48, p=0.001), while among
patients with locally advanced BCC (n=63), the
independently assessed response rate was 43 percent
(95% confidence interval, range 31–56, p<0.001) with 13
patients achieving complete response.143 Results endured
7.6 months for both cohorts. About 30 percent of patients
experienced adverse events, including serious adverse
events (25%) and seven deaths attributed to adverse
events. In a subsequent study of the same patients
offering 12 additional months of follow-up, the objective
response rate increased from 30 to 33 percent for
metastatic BCC patients and from 43 to 48 percent for
locally advanced BCC patients; the median duration of
response extended from 7.6 months to 9.5 months. There
were no new adverse events reported.144 
Sonidegib/erismodegib. Clinical trials are
underway for dose-ranging and safety for patients with
locally advanced or metastatic BCC being treated with
sonidegrib (also known as erismodegib and LDE225).
Sonidegrib is available in oral and topical formulations
(0.75%). In a study of eight patients with nevoid BCC (27
lesions, total) treated with 0.75% topical sonidegib or
vehicle twice daily, among the 13 lesions treated with the
active agent, three had a complete response and nine
partial responses after four weeks.145 A quality-of-life
study for patients taking 200 to 800mg of sonidegib
found both doses improved quality of life and had similar
tolerability.
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CUR61414. This new agent has been formulated as
a topical product. In a murine preclinical evaluation,
there was an in vivo down-regulation of Gli-1
expression, but a phase 1 study did not show efficacy in
human superficial BCC or nodular BCC.146
Saridegib (IPI-926). Saridegib (also known as IPI-
926) has entered phase 1 and 2 testing. It was originally
developed to treat chondrosarcoma, primary
myelofibrosis, pancreatic cancer, and various head and
neck cancers. 
Other SMO inhibitors. Smoothened (SMO)
inhibitors are currently being developed by several
pharmaceutical manufacturers. These agents include
BMS-833923 (Bristol-Myers-Squibb, currently in phase 1
and 2 testing); LEQ506 (Novartis, currently in phase 1
testing); PF-04449913 (Pfizer, currently in phase 1
testing); TAK-441 (Takeda Pharmaceuticals, currently in
phase 1 testing). 
Itraconazole, now in phase 2 clinical studies, binds
SMO at a distinct site from cyclopamine and inhibits the
growth of Hh-dependent BCCs and medullablastomas in
mice. Studies of an oral formulation itraconazole with
BCCs >4mm in size found it decreased cell proliferation,
reduced Hh pathway activity, and shrank tumor size.147,148
A topical formulation is also being evaluated. 
Large Congenital Nevi and Proliferative Nodules:
What’s New?
New recommendations have been published with
respect to the categorization of cutaneous features of
congenital melanocytic nevi (CMN), in particular, CMN
of the head (enlargement by factor 1.7), of trunk and
arms (enlargement factor 2.8), and legs (3.3).149 These
revisions may help better stratify risk and improve
dermatologic and interdisciplinary communication. The
phenotype observed is actually a reflection of the
patient’s underlying mutation, allowing for more precise
prediction of clinical behavior and possible therapeutic
response. 
A number of activating mutations in RAS genes have
been seen in large and giant nevi. Speckled lentiginous
nevi are often due to somatic-activating HRAS
mutations. Both large bathing trunk melanocytic nevi
and nevus spilus type LCMN are often caused by
activating mutations in the NRAS150 Recently, some cases
of LCMN have been reported to be cause by BRAF
mutations, specifically BRAF V600E.151 However, NRAS
Q61 mutations predominate as a cause of L/GCMN with
or without NCM.152
Proliferating nodule (PN) in GCMN. It can be
challenging to differentiate proliferative nodules (PNs)
from malignant melanomas (MMs) that occur in the
setting of GCMN.153 PNs are more likely to develop in the
first five years of life. Although typically benign (not
melanoma), clinicians should consider deep, firm, or
ulcerated nodules to be more concerning than soft,
superficial nodules. Interpretation of biopsies of
proliferative nodules and those in the newborn period
can be challenging and these specimens should ideally be
evaluated by dermatopathologists with experience in
understanding the findings. Ancillary tests, such as
genomic testing, are emerging, but remain of uncertain
value in terms of disease management.  PNs often
manifest with a blended appearance of expansive
nodules of epitheloid cells. There may be considerable
atypia and sometimes mitotic activity (malignant
melanoma in GCMN have increased mitoses relative to
PN and ulceration of the epidermis).154
Some report that incidence of PNs to occur in 3 to 19
percent of CGMN. The estimated lifetime risk for
melanoma developing in the setting of GCMN is
approximately 5 to 10 percent. Overall patterns
comparing PN and MM include the following:154
•   PNs are more common in GCMN than MMs
•   MMs exhibit more mitoses than PNs (1.67 vs. 12.5
mitoses per square mm)
•   MMs exhibit more ulceration than PNs
•   MMs show more partial chromosome gains
(6p25).
Phadke et al155 proposed a classification system
based on histopathological interpretation in PNs, but
recognized that their atypical features can make them
difficult to distinguish from melanoma. Atypical PNs
exhibited sharp demarcation, expansile growth,
epidermal effacement, and increased mistosis compared
to benign PNs. While molecular analysis of these
mutations has resulted in the detection of numerous
mutations, the practical diagnostic value of molecular
analysis remains unclear.
Conclusion
The Maui Derm conference convenes every year to
present the latest findings in dermatology, highlights of
new drug and device developments, and new care
paradigms for dermatologic patients in our changing
healthcare system. The opinions stated herein reflect
those of the authors speaking freely to their peers and
colleagues.
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